News - Adempas, Opsumit

Filter

Current filters:

AdempasOpsumit

Popular Filters

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

Actelion’s Opsumit approved by SwissMedic for PAH patients

Actelion’s Opsumit approved by SwissMedic for PAH patients

14-02-2014

Swiss biotech firm Actelion announced today that SwissMedic has approved Opsumit (macitentan) for pulmonary…

ActelionBiotechnologyCardio-vascularNorthern EuropeOpsumitRegulation

Actelion gains approval in Australia for Opsumit in PAH

Actelion gains approval in Australia for Opsumit in PAH

07-02-2014

Swiss biotech firm Actelion (SIX: ATLN) has received approval of Opsumit (macitentan) for the treatment…

ActelionAustraliaBiotechnologyCardio-vascularOpsumitRegulation

Japanese approval for Bayer’s riociguat for CTEPH

Japanese approval for Bayer’s riociguat for CTEPH

20-01-2014

German pharma major Bayer has received approval from the Ministry of Health, Labor and Welfare for riociguat,…

AdempasAsia-PacificBayerPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

Actelion’s PAH drug Opsumit approved in EU

Actelion’s PAH drug Opsumit approved in EU

22-12-2013

Switzerland-based Actelion has received European Commission approval for Opsumit (macitentan), a novel…

ActelionBiotechnologyEuropeOpsumitRegulationRespiratory and Pulmonary

Actelion receives Health Canada approval of Opsumit for PAH

Actelion receives Health Canada approval of Opsumit for PAH

13-11-2013

Swiss biotech firm Actelion (SIX: ATLN) says that Canada’s regulator Health Canada has approved its…

ActelionCanadaCardio-vascularNorth AmericaOpsumitPharmaceuticalRegulation

Actelion says PAH drug Opsumit now available in USA

Actelion says PAH drug Opsumit now available in USA

05-11-2013

Actelion has confirmed that Opsumit 10mg, an oral, dual endothelin receptor antagonist for pulmonary…

ActelionMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonary

Actelion presents positive trial data for Opsumit in PAH

Actelion presents positive trial data for Opsumit in PAH

29-10-2013

Swiss biotech firm Actelion will present data on the efficacy of Opsumit from the SERAPHIN study at CHEST…

ActelionBiotechnologyCardio-vascularNorth AmericaOpsumitResearch

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

US FDA gives nod to Actelion’s PAH drug Opsumit

US FDA gives nod to Actelion’s PAH drug Opsumit

21-10-2013

The US Food and Drug Administration has approved Actelion's pulmonary arterial hypertension drug Opsumit…

ActelionBiotechnologyCardio-vascularNorth AmericaOpsumitRegulation

Long-awaited vaccine brings hope for millions

Long-awaited vaccine brings hope for millions

11-10-2013

Here's our take on the week's top stories.

AdempasEuropeGlaxoSmithKlineIclusigNorth America

Actelion's Opsumit for PAH shows reduction in morbidity and mortality

10-09-2013

Swiss biotech firm Actelion (SIX: ATLN) has announced key morbidity and mortality data in pulmonary arterial…

ActelionOpsumitPharmaceuticalResearch

Actelion's Opsumit significantly reduced risk of morbidity/mortality events

29-08-2013

Results of SERAPHIN, the pivotal study with Switzerland-based Actelion's (SIX: ATLN) macitentan (trade…

ActelionBiotechnologymacitentanOpsumitResearchRespiratory and Pulmonary

Bayer's PAH/CTEPH drug gets unanimous backing from FDA advisory panel

07-08-2013

In what was largely expected following this week's briefing papers from US Food and Drug Administration…

AdempasBayerNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

FDA staffers back riociguat approval, but with modified dose

05-08-2013

On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

US pulmonologists views on PAH prescribing options

19-07-2013

US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

Actelion filing for EU approval of Opsumit accepted

23-11-2012

Switzerland-based Actelion (SIX: ATLN) says that it has submitted a Marketing Authorisation Application…

ActelionBiotechnologyEuropemacitentanOpsumitRegulationRespiratory and Pulmonary

Actelion files for US approval of Opsumit for PAH

23-10-2012

Europe's largest biotech company Actelion (SIX: ATLN) said yesterday that it has submitted a New Drug…

ActelionBiotechnologymacitentanNorth AmericaOpsumitRegulationResearchRespiratory and Pulmonary

Actelion post sales dip for first nine months, but back in profit

18-10-2012

Switzerland's Actelion (SIX: ATLN) posted financial results for the first nine months of 2012, with product…

ActelionBiotechnologyFinancialmacitentanOpsumitResearchRespiratory and Pulmonaryselexipag

Company Spotlight

Fibrotech

Fibrotech

Back to top